ArticlePLOS global public health2026
Tuberculosis comorbidities, multimorbidity and mortality amongst adults in South Africa: A prospective cohort study nested in a trial.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) comorbidities and multimorbidity - the presence of two or more concurrent diseases or health conditions - are major contributors to TB incidence and mortality. We investigated the prevalence and associated mortality of TB comorbidities and multimorbidity in South Africa. We conducted a prospective cohort study of adults ≥15 years with bacteriologically-confirmed pulmonary TB, nested within a trial in two provinces of South Africa. We investigated five TB key comorbidities (HIV, undernutrition, diabetes, smoking and alcohol use), and assessed all-cause mortality over 15 months using Cox regression. TB comorbidity was defined as TB with one comorbidity, and TB multimorbidity as TB with two or more comorbidities. Of 1997 participants, 1896 (95%) had mortality data available at 15 months. Median age was 38 (IQR 29-48) years, 1203/1997 (60%) were male, 86·2% (95% CI 84·6-86·6) had TB comorbidity and 47·5% (45·3-49·7) had TB multimorbidity. TB comorbidity peaked in participants aged 40-49 years (93% [90-95]), was more prevalent in men vs women (90%[88-91] vs 81%[78-84], p < 0·001), and in urban vs rural areas (88%[86-90] vs 84%[81-86], p = 0·005). Mortality was higher for participants with TB multimorbidity with two (16·0%[13·0-18·8], HR 1·88[1·20-2·95], p = 0·006) and three or more (19·9%[14·9-24·6], HR 2·58[1·56-4·24], p < 0·001) TB key comorbidities than those with no comorbidities (11·2%[7·17-15·0]) or TB comorbidity (10·6% [8·32-12·8]). The joint population attributable fraction for the TB key comorbidities on mortality was 60·0% (49·6-69·2%). TB comorbidities and multimorbidity are highly prevalent and significantly associated with mortality. People with TB should be offered screening and management of comorbidities to reduce their risk of death.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.